Riskpilot← Back to searchSign inGet full accessAscelia Pharma AB
ABActiveOrg 5565718797Hyllie Boulevard 34Manufacture of pharmaceutical preparations · NACE 2120Est. 199911 employees
Revenue 2024
SEK 214K
-39% vs 2023
EBITDA margin
-31558.9%
+38% vs 2023
Equity ratio
66.2%
Financial strength
Net profit 2024
SEK -75,8M
+28% vs 2023
| Revenue | SEK 214K | -39% |
| EBITDA | SEK -67,5M | +38% |
| Net profit | SEK -75,8M | +28% |
| Total assets | SEK 182,6M | +47% |
| Equity | SEK 121M | +8% |
| Employees | 11 | — |
Legal name
Ascelia Pharma AB
Org number
5565718797
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
4 juni 1999
Share capital
SEK 97 193 000
Employees
11 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas av en av ledamöterna i förening med Olafsson Corfitzen, Magnus Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska, direkt eller indirekt, bedriva utveckling, marknadsföring och försäljning av medicintekniska och pharmaceutiska produkter ävensom bedriva annan därmed förenlig verksamhet.
Address
Hyllie Boulevard 34
Email
moc@ascelia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 194 | 229 | 768 | 5 495 | 1 142 | 351 | 214 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −6 168 | −7 325 | −23 162 | −35 076 | −36 062 | −87 984 | −119 038 | −136 346 | −109 167 | −67 536 |
| Depreciation & amort. | −0 | — | −0 | — | — | — | — | — | — | — |
| EBIT | −6 168 | −7 325 | −23 162 | −35 076 | −36 062 | −87 984 | −119 038 | −136 346 | −109 167 | −67 536 |
| Net financials | −358 | −351 | 21 | −216 | −3 015 | −6 086 | 9 750 | 14 976 | 2 694 | −18 791 |
| Profit before tax | −6 526 | −7 676 | −23 140 | −35 010 | −39 077 | −94 070 | −109 288 | −121 371 | −105 563 | −75 831 |
| Tax | −0 | −0 | −0 | −50 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −6 526 | −7 676 | −23 140 | −35 060 | −39 077 | −94 070 | −109 288 | −121 371 | −105 563 | −75 831 |
| Item | 2016 | 2017 | 2018 | 2019 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 6 935 | 80 111 | 117 040 | 290 126 | 253 809 | 261 886 | 356 109 | 252 082 | 124 027 | 182 641 |
| Equity | −2 622 | 77 601 | 112 775 | 279 179 | 240 939 | 244 566 | 332 824 | 214 982 | 112 477 | 120 989 |
| Long-term debt | 8 000 | 0 | 0 | 146 | 96 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 557 | 2 510 | 4 265 | 10 801 | 12 774 | 17 320 | 23 285 | 37 101 | 11 551 | 61 652 |
| Total debt | 9 557 | 2 510 | 4 265 | 10 947 | 12 870 | 17 320 | 23 285 | 37 101 | 11 551 | 61 652 |
EBITDA margin
-31558.9%
This company
15.8%
Market median
-199840% vs market
20162024
Equity ratio
66.2%
This company
38.2%
Market median
+73% vs market
20162024
Return on equity
-62.7%
This company
18.4%
Market median
-441% vs market
20162024
Net profit margin
-35435.0%
This company
8.1%
Market median
-437569% vs market
20162024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162024
Debt / equity
0.51×
This company
0.62×
Market median
+18% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-07-01 – 2019-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-07-01 – 2016-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MO Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
MN Chief Auditor | Chief Auditor | 2024 | — | — |
JW Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
CJ Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Ascelia Pharma AB (this company)
Oncoral Pharma ApsBoard members of Ascelia Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Magnus Olafsson Corfitzen | Chief Executive Officer | 0 companies |
| Mikael Nilsson | Chief Auditor | 0 companies |
| Julie Waras Brogren | Chief Executive Officer | 0 companies |
| Carl Johan Fredrik Fogelberg | Chief Auditor | 0 companies |
| Lauren Geyer Barnes | Board of Directors | 0 companies |
| Bo Jesper Hansen | Board of Directors | 0 companies |
| Niels Mengel | Board of Directors | 0 companies |
| Hans Maier | Board of Directors | 0 companies |
| Marianne Kock | Board of Directors | 0 companies |
| Peter James Arthur Benson | Chairman | 0 companies |
| Anna Helena Christina Wennerström | Board of Directors | 0 companies |